Interferon beta-1a

Interferon beta-1a

Clinical data
ATC code	L03AB07 (WHO)
Pharmacokinetic data
Elimination half-life	10 hrs
Identifiers
IUPAC name Human interferon beta
CAS Number	145258-61-3
DrugBank	BTD00093
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}
Chemical and physical data
Formula	C908H1408N246O252S7
Molar mass	20027.0 g/mol

WikiDoc Resources for Interferon beta-1a
Articles
Most recent articles on Interferon beta-1a Most cited articles on Interferon beta-1a Review articles on Interferon beta-1a Articles on Interferon beta-1a in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Interferon beta-1a Images of Interferon beta-1a Photos of Interferon beta-1a Podcasts & MP3s on Interferon beta-1a Videos on Interferon beta-1a
Evidence Based Medicine
Cochrane Collaboration on Interferon beta-1a Bandolier on Interferon beta-1a TRIP on Interferon beta-1a
Clinical Trials
Ongoing Trials on Interferon beta-1a at Clinical Trials.gov Trial results on Interferon beta-1a Clinical Trials on Interferon beta-1a at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Interferon beta-1a NICE Guidance on Interferon beta-1a NHS PRODIGY Guidance FDA on Interferon beta-1a CDC on Interferon beta-1a
Books
Books on Interferon beta-1a
News
Interferon beta-1a in the news Be alerted to news on Interferon beta-1a News trends on Interferon beta-1a
Commentary
Blogs on Interferon beta-1a
Definitions
Definitions of Interferon beta-1a
Patient Resources / Community
Patient resources on Interferon beta-1a Discussion groups on Interferon beta-1a Patient Handouts on Interferon beta-1a Directions to Hospitals Treating Interferon beta-1a Risk calculators and risk factors for Interferon beta-1a
Healthcare Provider Resources
Symptoms of Interferon beta-1a Causes & Risk Factors for Interferon beta-1a Diagnostic studies for Interferon beta-1a Treatment of Interferon beta-1a
Continuing Medical Education (CME)
CME Programs on Interferon beta-1a
International
Interferon beta-1a en Espanol Interferon beta-1a en Francais
Business
Interferon beta-1a in the Marketplace Patents on Interferon beta-1a
Experimental / Informatics
List of terms related to Interferon beta-1a

Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [1] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.

Overview

Interferon beta-1a is a drug in the interferon family used to treat multiple sclerosis (MS). It is produced by mammalian cells while Interferon beta-1b is produced in modified E. coli. Interferons have been shown to have about a 30–35% reduction in the rate of MS relapses, and to slow the progression of disability in MS patients. None of the products on the market is a cure, but patients today who start early on Interferons may beneficially alter the natural course of the disease.

There are two principal competitors in the market for this drug and one biogeneric / biosimilar one:

• Biogen Idec's Avonex®
• Serono's Rebif®
• CinnaGen's CinnoVex®

It is believed that Interferon beta based drugs achieve their beneficial effect on MS progression via their anti-inflammatory properties. Studies have also determined that Interferon beta improves the integrity of the blood-brain barrier (BBB), which generally breaks down in MS patients, allowing increasing amounts of undesirable substances to reach the brain. This strengthening of the BBB may be a contributing factor to Interferon-Beta's beneficial effects. These studies were carried out in vitro (outside a living organism; a "petri dish" experiment), so it does not necessarily mean it works the same in people.

Nonetheless, Interferons have side effects. The two main ones are flu-like symptoms, and injection-site reactions. The flu-like symptoms tend to happen immediately after the injection, and last for about half a day. In many patients, these symptoms diminish over time, but some patients continue to experience them over the long term. One can mitigate these symptoms by using a dose that is injected less frequently, and by taking the medication before bedtime. The injection-site reactions can be mitigated by rotating injection sites, or by using one of the medications that requires less frequent injections. Side effects are often onerous enough that many patients ultimately discontinue taking Interferons (or Copaxone®, one of the other disease-modifying therapies requiring daily or weekly injections).

The most commonly reported side effects are injection site disorders, flu-like symptoms, elevation of liver enzymes and blood cell abnormalities. Patients with depression, seizure disorders, or liver problems, should discuss treatment with Rebif with their doctors.

While these drugs improve certain diagnostic test results, many patients report no perceived improvement, along with serious side-effects that substantially reduce quality of life. It is important to recognize that these drugs are intended to treat symptoms and possibly delay disease progression, but do not provide a cure to multiple sclerosis. Furthermore, tolerance develops over time in some patients, due to the development of "neutralizing antibodies," which reduces the effectiveness of these drugs, while side effects may persist even after discontinuation. See patient ratings of Rebif and Avonex, below.

A one month supply of Avonex or Rebif costs $1600 USD.

Avonex

Avonex is administered once per week intramuscular injection using a 23-gauge 1.25" needle, however a 25-gauge 1" needle has been approved and may be substituted by a physician.[2] It is produced by the Biogen Idec biotechnology company. Originally it was under competition protection in the US under the Orphan Drug Act.

Avonex was approved in the US in 1996, and in Europe in 1997, and is registered in more than 80 countries worldwide. It is the leading MS therapy in the US, with around 40% of the overall market, and in Europe, with around 30% of the overall market.

Biogen Idec markets Avonex in two formulations: the original powder form, which requires the patient to reconstitute it before administration; and a newer pre-reconstituted "liquid Avonex" syringe kit.

Rebif

Rebif is a subcutaneous injection dosed three times per week. It comes in pre-filled syringes with a 29 gauge needle, thinner than the needle supplied with Avonex. It can be used with the Rebiject II autoinjector.

Rebif is a disease-modifying drug used to treat relapsing forms of multiple sclerosis and is similar to the interferon beta protein produced by the human body. Interferon helps modulate the body’s immune system, fight disease and reduce inflammation. It is co-marketed by Serono and Pfizer in the US under an exception to the Orphan Drug Act.

Rebif was approved in Europe in 1998 and in the US in 2002. It is registered in more than 80 countries worldwide. Rebif is available in a 22 mcg and 44 mcg ready-to-use pre-filled syringe and can be stored at room temperature for up to 30 days if a refrigerator is not available.

CinnoVex

CinnoVex is the trade name of recombinant Interferon beta 1-a, which is manufactured as biosimilar/biogeneric in Iran.
CinnoVex is available as powder in 2 ml vials along with injectable distilled water. Each dose contains 30 micrograms of active protein which is equal to 6 million international unit of activity.
An interferon-beta protein developed at the Fraunhofer Institute for Interfacial Engineering and Biotechnology IGB, Stuttgart,Germany, in collaboration with CinnaGen company, Tehran, Iran,is now the first therapeutic protein from a Fraunhofer laboratory to be approved as biogeneric / biosimilar medicine.
An interferon-beta-1a, whose biotechnical engineering and production up to the pilot scale was optimized at the Fraunhofer Institute for Interfacial Engineering and Biotechnology IGB in collaboration with CinnaGen Company, has now been approved as biogeneric by the Iranian Food and Drug Administration (IFDA).
A more soluble variant of interferon-beta also engineered at the IGB is for example being clinically investigated by the Vakzine Projekt Management (VPM) GmbH in Braunschweig, Germany.

Related drugs

Closely related is Interferon beta-1b, also may be indicated for Multiple Sclerosis, and with a very similar drug profile. Interferon beta-1b is marketed only by Berlex in the US as Betaseron and outside the US as Betaferon by Schering AG.

See also

• Interferon beta-1b